Gu Dongqing, Chen Wei, Mi Youjun, Gong Xueli, Luo Tao, Bao Lang
Laboratory of Infection and Immunity, School of Basic Medical Sciences, West China Center of Medical Science, Sichuan University, Chengdu 610041, China.
Laboratory of Infection and Immunity, School of Basic Medical Sciences, West China Center of Medical Science, Sichuan University, Chengdu 610041, China
Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):385-90. doi: 10.1093/abbs/gmw010. Epub 2016 Feb 27.
Tuberculosis remains a major global health problem and effective vaccines are urgently needed. In this study, we used the combined DNA- and protein-based vaccines of immunodominant antigen Rv0577 to boost BCG and evaluated their immunogenicity in BALB/c mice. Our data suggest that the booster vaccine may substantially enhance the immunogenicity of BCG and strengthen both CD4+ T cell-mediated Th1 and CD8+ T cell-mediated cytolytic responses. Compared with the protein-based vaccine, the DNA-based vaccine can induce more durable Th1 immune response, characterized by high levels of antibody response, proliferation response, percentages of CD4+/CD8+ and cytokine secretion in antigen-stimulated splenocyte cultures. In conclusion, we for the first time, developed a protein- and plasmid DNA-based booster vaccine based on Rv0577. Our findings suggest that antigen Rv0577-based DNA vaccine is immunogenic and can efficiently boost BCG, which could be helpful in the design of an efficient vaccination strategy against TB.
结核病仍然是一个重大的全球健康问题，迫切需要有效的疫苗。在本研究中，我们使用基于免疫显性抗原Rv0577的DNA和蛋白质联合疫苗加强卡介苗免疫，并在BALB/c小鼠中评估了它们的免疫原性。我们的数据表明，加强疫苗可显著增强卡介苗的免疫原性，并增强CD4+T细胞介导的Th1反应和CD8+T细胞介导的细胞溶解反应。与基于蛋白质的疫苗相比，基于DNA的疫苗可诱导更持久的Th1免疫反应，其特征在于抗原刺激的脾细胞培养物中高水平的抗体反应、增殖反应、CD4+/CD8+百分比和细胞因子分泌。总之，我们首次开发了基于Rv0577的蛋白质和质粒DNA加强疫苗。我们的研究结果表明，基于抗原Rv0577的DNA疫苗具有免疫原性，可有效加强卡介苗免疫，这可能有助于设计针对结核病的有效疫苗接种策略。
